Srinivas Viswanathan, M.D., Ph.D., was a clinical fellow just a couple years into his physician-scientist training when he met two young patients who had a rare type of kidney cancer. The standard treatments didn’t work for them. As a clinician, he knew there was little he could do. As a scientist, he wanted to do better.
More than a decade later, Viswanathan’s lab at the Dana-Farber Cancer Institute (DFCI) is focused largely on doing better. The clinical quandary turned into a research question that he’s been pursuing ever since, starting as a side project in his lab and now a major effort. The ultimate goal: informing the development of the kinds of therapeutics those young patients he met in fellowship training needed…
Read the full article here.
